FL115

Phase 2Small molecule

SSuzhou Forlong Biotechnology Co., Ltd

FL115 is one of 71 small molecule programs targeting Advanced Solid Tumours. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced Solid TumoursNot yet recruiting

Metastatic Solid TumorsActive, not recruiting

Bladder CancerRecruiting

Advanced Solid TumoursPhase 1

Not yet recruiting

Metastatic Solid TumorsPhase 1

Active, not recruiting

Bladder CancerPhase 2

Recruiting

Competition

Competitive Landscape

118 competitors in Bladder Cancer

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

52 2

Keytruda

Merck & Co.

Phase 3

27 3

Opdivo

Bristol-Myers Squibb

Phase 3

20 4

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

57 5

Tecentriq

Roche

Phase 3

16 6

Imfinzi

AstraZeneca

Phase 3

16 7

Trexall

Jazz Pharmaceuticals

Phase 3

12 8

Padcev

Pfizer

Phase 3

8 9

Imjudo

AstraZeneca

Phase 3

8 10

Gemzar

GGynecologic Oncology Group

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 1/2Recruiting

Bladder Cancer

NCT07122414

Q3 2029

Phase 1Not yet recruiting

Advanced Solid Tumours

NCT07785193

Clinical

Trials by Indication[1]

Metastatic Solid Tumors1 trial

A Study of FL115 Monotherapy in Unresectable or Metastatic Solid Tumors

Active, not recruiting·SSuzhou Forlong Biotechnology Co., Ltd·Phase 1·NCT07131189·30 enrolled

Bladder Cancer1 trial

A Study of Intravesical FL115 Alone or in Combination With BCG in Non-Muscle Invasive Bladder Cancer

Recruiting·SSuzhou Forlong Biotechnology Co., Ltd·Phase 1/2·NCT07122414·80 enrolled

Advanced Solid Tumours1 trial

An Open-label, Multicenter, Dose-escalation Phase Ib Clinical Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of FL115 Injection Administered Subcutaneously as Monotherapy in Participants With Advanced Solid Tumours

Not yet recruiting·SSuzhou Forlong Biotechnology Co., Ltd·Phase 1·NCT07785193·29 enrolled

Unspecified1 trial

First-in-Human, Phase I, Open-label, Multicenter, Dose Escalation Clinical Study

Completed·SSuzhou Forlong Biotechnology Co., Ltd·Phase 1·NCT06130722·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for FL115. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — FL115 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for FL115. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Suzhou Forlong Biotechnology Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSuzhou Forlong Biotechnology Co., Ltd

FL115

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q3 2029

Trials by Indication[1]

Metastatic Solid Tumors1 trial

Bladder Cancer1 trial

Advanced Solid Tumours1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News